Skip to main content
. Author manuscript; available in PMC: 2010 Apr 15.
Published in final edited form as: Clin Cancer Res. 2009 Apr 7;15(8):2808–2817. doi: 10.1158/1078-0432.CCR-08-1953

Figure 5. Therapeutic efficacy of bortezomib plus milatuzumab in MM-bearing SCID mice.

Figure 5

Figure 5

Figure 5

A, SCID mice were immunosuppressed by pretreatment with fludarabine phosphate and cyclophosphamide 3 d before injection of CAG cells. Treatments were given twice weekly for 4 wk, starting 1 d after injection of the CAG cells. SCID mice bearing CAG- (B) or KMS11- (C) were treated with bortezomib, milatuzumab, and mixtures of milatuzumab + bortezomib. Treatments for experiments shown in panels B and C were given as 2 i.p. doses/wk for 3 wk, initiated on day 5 after injection of tumor cells.